Eli Lilly's stock price rise continues unabated in 2023, backed by strong topline growth in 2023 and a sunny outlook for 2024.Its diabetes treatments look particularly encouraging, with Mounjaro's 11x...
Source LinkEli Lilly's stock price rise continues unabated in 2023, backed by strong topline growth in 2023 and a sunny outlook for 2024.Its diabetes treatments look particularly encouraging, with Mounjaro's 11x...
Source Link
Comments